Novartis Lp(a)HORIZON: pelacarsen failed to reduce heart attacks and strokes
Louis shares the first outcome-trial result for an Lp(a)-lowering drug: topline data from Novartis say pelacarsen lowered Lp(a) but did not show reduced cardiovascular risk overall. He says the result seriously questions whether Lp(a) is directly causal, noting only a press announcement is available so far.
